Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH mutations.

  • 0 views
  • 26 Apr, 2021
  • 3 locations
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML MDS and MDS/MPN

/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and are planning to have an allogeneic hematopoietic stem cell transplant ("bone marrow transplant"). The goal of this research study is to (1

KRAS
fludarabine
TP53
myelomonocytic leukemia
cancer
  • 31 views
  • 30 Jan, 2021
  • 1 location
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib

direct bilirubin
myeloproliferative neoplasm
mds/mpn-u
absolute neutrophil count
cancer
  • 65 views
  • 26 Jan, 2021
  • 1 location
Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm.

azacitidine
astx727
myeloproliferative disorder
bone marrow procedure
sgi-110
  • 17 views
  • 20 Mar, 2021
  • 5 locations
Salsalate Venetoclax and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

/myeloproliferative disease that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and azacitidine work in different ways to stop the growth of

TP53
myelomonocytic leukemia
cancer
secondary aml
neoadjuvant therapy
  • 0 views
  • 26 Jan, 2021
  • 1 location
Azacitidine Venetoclax and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

positive acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome/myeloproliferative neoplasm that has come back (recurrent) or has not responded to treatment

  • 8 views
  • 28 Mar, 2021
  • 1 location
Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence

of recurrence after allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in the blood system. Sex and safety. At the screening/baseline period, informed consent is obtained and the

azacitidine
absolute neutrophil count
acute graft versus host disease
acute graft-versus-host disease
allogeneic hematopoietic stem cell transplant
  • 0 views
  • 26 Jan, 2021
  • 1 location
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

myeloproliferative neoplasms (MPN), and chronic or accelerated phase MPN-unclassifiable (MPN-U) and MDS-MPN. Blast crisis phase of MPNs are considered secondary AML and will be included in the AML cohort.

  • 0 views
  • 09 May, 2021
  • 3 locations
Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias

. 4. Myeloproliferative disorder (MPD) with eosinophilia, eosinophilic leukemia or chronic myelomonocytic leukemia [myeloproliferative disorders/myelodysplastic syndromes (MPD/MDS

myelodysplastic/myeloproliferative neoplasm
myelomonocytic leukemia
leukemia
bone marrow procedure
bone marrow transplant
  • 10 views
  • 07 Nov, 2020
  • 14 locations
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

The aim of the research in this study is to make participants' transplant safer by reducing the risk of developing GVHD and GVHD-related complications by giving participants a dose of the drug tocilizumab in addition to the standard approach for GVHD prevention. Tocilizumab reduces the risk of inflammation by blocking …

stem cell transplantation
umbilical cord blood transplantation
cytogenetic abnormality
consolidation chemotherapies
growth factor
  • 71 views
  • 09 Mar, 2021
  • 1 location